Prophylaxis and treatment of invasive candidiasis in the intensive care setting

Review

Abstract

The term “invasive candidiasis” encompasses a group of infections of increasing relevance in the intensive care setting. Prophylaxis is an attractive strategy when dealing with diseases of high prevalence, morbidity, and mortality. The success of prophylaxis is determined by the selection of a population at high risk and the use of the safest and most effective drug. Although risk factors for this disease are known, risk assessment strategies need to be developed to predict a high likelihood of disease so that targeted prophylaxis can be offered. Recent advances in antifungal therapy, such as development of the azoles and echinocandins, have resulted in excellent prophylactic and therapeutic choices for the management of this problem.

References

  1. 1.
    Jarvis WR (1995) Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 20:1526–1530PubMedGoogle Scholar
  2. 2.
    Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, Pfaller M, Edwards JE Jr, Jarvis W, Dawson J, Wenzel RP (1999) National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 29:253–258PubMedGoogle Scholar
  3. 3.
    Kullberg BJ, Oude Lashof AM (2002) Epidemiology of opportunistic invasive mycoses. Eur J Med Res 7:183–191PubMedGoogle Scholar
  4. 4.
    Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, Calandra T, Glauser MP, Tauber MG, Pittet D (2004) Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000. Clin Infect Dis 38:311–320CrossRefPubMedGoogle Scholar
  5. 5.
    Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP (2001) Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The national epidemiology of mycosis survey. Clin Infect Dis 33:177–186PubMedGoogle Scholar
  6. 6.
    Leleu G, Aegerter P, Guidet B (2002) Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 17:168–175CrossRefPubMedGoogle Scholar
  7. 7.
    Benjamin DK Jr, Garges H, Steinbach WJ (2003) Candida bloodstream infection in neonates. Semin Perinatol 27:375–383PubMedGoogle Scholar
  8. 8.
    Grohskopf LA, Sinkowitz-Cochran RL, Garrett DO, Sohn AH, Levine GL, Siegel JD, Stover BH, Jarvis WR (2002) A national point-prevalence survey of pediatric intensive care unit-acquired infections in the United States. J Pediatr 140:432–438CrossRefPubMedGoogle Scholar
  9. 9.
    Vincent JL, Anaissie E, Bruining H, Demajo W, el-Ebiary M, Haber J, Hiramatsu Y, Nitenberg G, Nystrom PO, Pittet D, Rogers T, Sandven P, Sganga G, Schaller MD, Solomkin J (1998) Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 24:206–216CrossRefPubMedGoogle Scholar
  10. 10.
    Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D (2003) Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37:1172–1177CrossRefPubMedGoogle Scholar
  11. 11.
    Rentz AM, Halpern MT, Bowden R (1998) The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 27:781–788PubMedGoogle Scholar
  12. 12.
    Rex JH, Sobel JD (1999) Preventing intra-abdominal candidiasis in surgical patients. Crit Care Med 27:1033–1034CrossRefPubMedGoogle Scholar
  13. 13.
    Rex JH, Sobel JD (2001) Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 32:1191–1200CrossRefPubMedGoogle Scholar
  14. 14.
    Sobel JD, Rex JH (2001) Invasive candidiasis: turning risk into a practical prevention policy? Clin Infect Dis 33:187–190CrossRefPubMedGoogle Scholar
  15. 15.
    Eggimann P, Garbino J, Pittet D (2003) Management of Candida species infections in critically ill patients. Lancet Infect Dis 3:772–785CrossRefPubMedGoogle Scholar
  16. 16.
    Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, Pfaller MA (2002) Epidemiology of candidemia: 3-year results from the Emerging Infections and the Epidemiology of Iowa Organisms Study. J Clin Microbiol 40:1298–1302CrossRefPubMedGoogle Scholar
  17. 17.
    Wenzel RP (1995) Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 20:1531–1534PubMedGoogle Scholar
  18. 18.
    Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R (1994) Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 220:751–758PubMedGoogle Scholar
  19. 19.
    Pelz RK, Hendrix CW, Swoboda SM, Diener-West M, Merz WG, Hammond J, Lipsett PA (2001) Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 233:542–548CrossRefPubMedGoogle Scholar
  20. 20.
    Tran LT, Auger P, Marchand R, Carrier M, Pelletier C (1997) Epidemiological study of Candida spp. colonization in cardiovascular surgical patients. Mycoses 40:169–173PubMedGoogle Scholar
  21. 21.
    Munoz P, Burillo A, Bouza E (2000) Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit. Int J Antimicrob Agents 15:83–90CrossRefPubMedGoogle Scholar
  22. 22.
    Yazdanparast K, Auger P, Marchand R, Carrier M, Cartier R (2001) Predictive value of Candida colonization index in 131 patients undergoing two different cardiovascular surgical procedures. J Cardiovasc Surg (Torino) 42:339–343Google Scholar
  23. 23.
    Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D (2002) Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 28:1708–1717CrossRefPubMedGoogle Scholar
  24. 24.
    Paphitou NI, Ostrosky-Zeichner L, Rex JH (2002) Developing criteria for risk-stratified prophylaxis (PRX) of invasive candidiasis (IC) in the ICU. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract no. M-1239Google Scholar
  25. 25.
    Ostrosky-Zeichner L, Sable C, Sobel J, Alexander B, Donowitz G, Kan V, Kauffman CA, Kett D, Larsen R, Morrison V, Nucci M, Pappas PG, Bradley M, Major S, Wallace D, Rex JH (2004) Multicenter retrospective development and validation of a clinical prediction rule for invasive candidiasis (IC) in the intensive care setting. In: Focus on Fungal Infections 14, Abstract no. 51Google Scholar
  26. 26.
    Dupont H, Bourichon A, Paugam-Burtz C, Mantz J, Desmonts JM (2003) Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 31:752–757CrossRefPubMedGoogle Scholar
  27. 27.
    Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis G, Chiolero R, Pannatier A, Schilling J, Geroulanos S, Glauser MP, Calandra T (1999) Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 27:1066–1072CrossRefPubMedGoogle Scholar
  28. 28.
    Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7–14CrossRefPubMedGoogle Scholar
  29. 29.
    Swoboda SM, Merz WG, Lipsetta PA (2003) Candidemia: the impact of antifungal prophylaxis in a surgical intensive care unit. Surg Infect (Larchmt) 4:345–354CrossRefGoogle Scholar
  30. 30.
    Odds FC, Brown AJ, Gow NA (2003) Antifungal agents: mechanisms of action. Trends Microbiol 11:272–279CrossRefPubMedGoogle Scholar
  31. 31.
    Steinbach WJ, Perfect JR (2003) Newer antifungal therapy for emerging fungal pathogens. Int J Infect Dis 7:5–20CrossRefPubMedGoogle Scholar
  32. 32.
    Groll AH, Walsh TJ (2002) Antifungal chemotherapy: advances and perspectives. Swiss Med Wkly 132:303–311PubMedGoogle Scholar
  33. 33.
    Denning DW (2002) Echinocandins: a new class of antifungal. J Antimicrob Chemother 49:889–891CrossRefPubMedGoogle Scholar
  34. 34.
    Garbino J, Kolarova L, Rohner P, Lew D, Pichna P, Pittet D (2002) Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine (Baltimore) 81:425–433CrossRefGoogle Scholar
  35. 35.
    Snydman DR (2003) Shifting patterns in the epidemiology of nosocomial Candida infections. Chest 123(Suppl 5):500S–503SCrossRefPubMedGoogle Scholar
  36. 36.
    Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ (1993) Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis 17:103–109CrossRefPubMedGoogle Scholar
  37. 37.
    Alexander BD (2002) Diagnosis of fungal infection: new technologies for the mycology laboratory. Transpl Infect Dis 4 (Suppl 3):32–37CrossRefPubMedGoogle Scholar
  38. 38.
    Erjavec Z, Verweij PE (2002) Recent progress in the diagnosis of fungal infections in the immunocompromised host. Drug Resist Updat 5:3–10CrossRefPubMedGoogle Scholar
  39. 39.
    Chakrabarti A, Roy P, Kumar D, Sharma BK, Chugh KS, Panigrahi D (1994) Evaluation of three serological tests for detection of anti-candidal antibodies in diagnosis of invasive candidiasis. Mycopathologia 126:3–7PubMedGoogle Scholar
  40. 40.
    Phillips P, Dowd A, Jewesson P, Radigan G, Tweeddale MG, Clarke A, Geere I, Kelly M (1990) Nonvalue of antigen detection immunoassays for diagnosis of candidemia. J Clin Microbiol 28:2320–2326PubMedGoogle Scholar
  41. 41.
    Christensson B, Sigmundsdottir G, Larsson L (1999) d-arabinitol—a marker for invasive candidiasis. Med Mycol 37:391–396CrossRefPubMedGoogle Scholar
  42. 42.
    Reiss E, Obayashi T, Orle K, Yoshida M, Zancope-Oliveira RM (2000) Non-culture based diagnostic tests for mycotic infections. Med Mycol 38(Suppl 1):147–159PubMedGoogle Scholar
  43. 43.
    Stephan F, Bah MS, Desterke C, Rezaiguia-Delclaux S, Foulet F, Duvaldestin P, Bretagne S (2002) Molecular diversity and routes of colonization of Candida albicans in a surgical intensive care unit, as studied using microsatellite markers. Clin Infect Dis 35:1477–1483CrossRefPubMedGoogle Scholar
  44. 44.
    Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, Edwards JE (2000) Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 30:662–678CrossRefPubMedGoogle Scholar
  45. 45.
    Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE (2004) Guidelines for treatment of candidiasis. Clin Infect Dis 38:161–189CrossRefPubMedGoogle Scholar
  46. 46.
    Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP et al (1994) A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 331:1325–1330CrossRefPubMedGoogle Scholar
  47. 47.
    Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020–2029CrossRefPubMedGoogle Scholar
  48. 48.
    Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino JE, Chapman S, Horowitz HW, Edwards JE, Dismukes WE (2003) A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37:634–643CrossRefPubMedGoogle Scholar
  49. 49.
    Rex JH, Pfaller MA (2002) Has antifungal susceptibility testing come of age? Clin Infect Dis 35:982–989CrossRefPubMedGoogle Scholar
  50. 50.
    Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Gosey LL, Odds FC, Rinaldi MG, Sheehan DJ, Warnock DW (2001) Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 14:643–658CrossRefPubMedGoogle Scholar
  51. 51.
    Pfaller MA, Rex JH, Rinaldi MG (1997) Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis 24:776–784PubMedGoogle Scholar
  52. 52.
    Nucci M, Colombo AL, Silveira F, Richtmann R, Salomao R, Branchini ML, Spector N (1998) Risk factors for death in patients with candidemia. Infect Control Hosp Epidemiol 19:846–850PubMedGoogle Scholar
  53. 53.
    Nucci M, Anaissie E (2002) Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis 34:591–599CrossRefPubMedGoogle Scholar
  54. 54.
    Shin JH, Kee SJ, Shin MG, Kim SH, Shin DH, Lee SK, Suh SP, Ryang DW (2002) Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol 40:1244–1248CrossRefPubMedGoogle Scholar
  55. 55.
    Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA (2002) Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 46:1773–1780CrossRefPubMedGoogle Scholar
  56. 56.
    Nucci M, Anaissie E (2001) Revisiting the source of candidemia: skin or gut? Clin Infect Dis 33:1959–1967CrossRefPubMedGoogle Scholar
  57. 57.
    Rodriguez-Adrian LJ, King RT, Tamayo-Derat LG, Miller JW, Garcia CA, Rex JH (2003) Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology. Medicine (Baltimore) 82:187–202CrossRefGoogle Scholar
  58. 58.
    Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, Brass C, Vazquez JA, Chapman SW, Horowitz HW et al (2003) A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 36:1221–1228CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  1. 1.Division of Infectious DiseasesUniversity of Texas Health Science Center at HoustonHoustonUSA

Personalised recommendations